Fresenius Medical Care AG & Co. (FMS) Upgraded by UBS Group to Neutral

Fresenius Medical Care AG & Co. (NYSE:FMS) was upgraded by equities research analysts at UBS Group from a “sell” rating to a “neutral” rating in a research report issued on Thursday, www.briefing.com reports.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada reissued a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care AG & Co. in a report on Wednesday, September 13th. Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday. SunTrust Banks set a $62.00 target price on shares of Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a report on Thursday, December 21st. DZ Bank reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, November 13th. Finally, Morgan Stanley cut shares of Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. Fresenius Medical Care AG & Co. presently has a consensus rating of “Hold” and a consensus price target of $53.00.

Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.30 during mid-day trading on Thursday, hitting $52.64. 83,100 shares of the stock were exchanged, compared to its average volume of 101,350. The company has a market capitalization of $32,141.47, a PE ratio of 23.61, a P/E/G ratio of 2.18 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98. Fresenius Medical Care AG & Co. has a 52-week low of $39.46 and a 52-week high of $52.96.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Harding Loevner LP raised its holdings in Fresenius Medical Care AG & Co. by 4,271.1% in the 3rd quarter. Harding Loevner LP now owns 163,837,558 shares of the company’s stock valued at $31,245,000 after buying an additional 160,089,385 shares during the last quarter. Cambiar Investors LLC raised its holdings in Fresenius Medical Care AG & Co. by 3.8% in the 3rd quarter. Cambiar Investors LLC now owns 2,695,714 shares of the company’s stock valued at $131,793,000 after buying an additional 99,234 shares during the last quarter. Royal Bank of Canada raised its holdings in Fresenius Medical Care AG & Co. by 6.4% in the 2nd quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock valued at $24,248,000 after buying an additional 30,119 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Fresenius Medical Care AG & Co. by 8.9% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 431,183 shares of the company’s stock valued at $21,081,000 after buying an additional 35,064 shares during the last quarter. Finally, Jarislowsky Fraser Ltd raised its holdings in Fresenius Medical Care AG & Co. by 1.2% in the 3rd quarter. Jarislowsky Fraser Ltd now owns 294,871 shares of the company’s stock valued at $14,416,000 after buying an additional 3,556 shares during the last quarter. Institutional investors and hedge funds own 3.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fresenius Medical Care AG & Co. (FMS) Upgraded by UBS Group to Neutral” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/04/fresenius-medical-care-ag-co-fms-upgraded-by-ubs-group-to-neutral.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply